Insider Buying: Microbix Biosystems (TSE:MBX) Director Buys 69,000 Shares of Stock

Microbix Biosystems Inc. (TSE:MBX – Get Free Report) Director Martin Marino purchased 69,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were purchased at an average price of C$0.26 per share, for a total transaction of C$17,940.00. Following the purchase, the director owned 1,860,667 shares of the company’s stock, valued at approximately C$483,773.42. This trade represents a 3.85% increase in their position.

Martin Marino also recently made the following trade(s):

Get Microbix Biosystems alerts:

• On Wednesday, May 27th, Martin Marino purchased 24,500 shares of Microbix Biosystems stock. The shares were purchased at an average price of C$0.26 per share, for a total transaction of C$6,370.00.

Microbix Biosystems Stock Down 1.8%

Shares of Microbix Biosystems stock traded down C$0.01 during trading on Thursday, hitting C$0.28. 94,500 shares of the stock traded hands, compared to its average volume of 61,453. The firm has a market cap of C$37.81 million, a P/E ratio of -6.71 and a beta of 0.48. The company has a current ratio of 5.35, a quick ratio of 5.57 and a debt-to-equity ratio of 27.03. Microbix Biosystems Inc. has a 52-week low of C$0.21 and a 52-week high of C$0.34. The stock’s fifty day simple moving average is C$0.24 and its 200 day simple moving average is C$0.24.

Microbix Biosystems (TSE:MBX – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported C($0.01) EPS for the quarter. Microbix Biosystems had a negative net margin of 38.62% and a negative return on equity of 21.02%. The firm had revenue of C$3.38 million for the quarter. On average, equities analysts predict that Microbix Biosystems Inc. will post 0.02 earnings per share for the current fiscal year.

About Microbix Biosystems

(Get Free Report)

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.

Featured Stories

• Five stocks we like better than Microbix Biosystems
• 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
• Snowflake and the Snowballing Impact of its AI Flywheel
• AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
• These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying

Receive News & Ratings for Microbix Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbix Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.